Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Drug Value Frameworks Gain Traction, Patients Seek More Input

Executive Summary

'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.

You may also be interested in...



Patients’ View Of Drug Value Is Focus Of Avalere/FasterCures Framework

Cost considerations will be limited to those borne by patients under value framework that is expected to be used initially to support patient-clinician decisions on appropriate treatment.

Drug Pricing: With "Value" Debate In Full Swing, ICER’s Influence Grows

The Institute for Clinical and Economic Review has invited feedback on its methodology for calculating a drug's recommended price range. Industry response has been critical, but pharma can no longer afford to merely oppose value frameworks. It needs to create strategies for a world in which such frameworks are a permanent and influential part of the pricing and reimbursement landscape.

ICER Eyes QALY Ratios, Budget Impacts In Methods Review

Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.

Related Content

Topics

UsernamePublicRestriction

Register

PS119214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel